CIP
CRL icon

Cornerstone Investment Partners’s Charles River Laboratories CRL Stock Holding History

Cornerstone Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$839K Buy
3,700
+106
+3% +$18.9K 0.03% 58
2026
Q1 		$620K Buy
3,594
+84
+2% +$15.6K 0.03% 56
2025
Q4 		$700K Buy
3,510
+688
+24% +$125K 0.03% 53
2025
Q3 		$442K Buy
2,822
+767
+37% +$122K 0.02% 73
2025
Q2 		$312K Buy
2,055
+121
+6% +$16.1K 0.01% 99
2025
Q1 		$291K Sell
1,934
-6
-0.3% -$1.01K 0.01% 93
2024
Q4 		$358K Buy
1,940
+69
+4% +$13.3K 0.02% 91
2024
Q3 		$369K Buy
1,871
+2
+0.1% +$416 0.02% 91
2024
Q2 		$386K Buy
1,869
+472
+34% +$107K 0.02% 96
2024
Q1 		$379K Buy
1,397
+25
+2% +$5.97K 0.02% 105
2023
Q4 		$324K Buy
+1,372
New +$270K 0.02% 109

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Cornerstone Investment Partners's CRL Position: Q2 2026 in Review

Cornerstone Investment Partners increased its Charles River Laboratories (CRL) stake by 2.9% in Q2 2026, buying an estimated $18.9K and bringing the position to 3,700 shares worth $839K. The position accounts for 0.03% of the portfolio, ranked #58.

Cornerstone Investment Partners first reported a position in CRL in Q4 2023 and has held it in 11 quarters since. 260 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Cornerstone Investment Partners held 3,700 shares of Charles River Laboratories worth $839K as of Q2 2026.
  • Cornerstone Investment Partners bought 106 Charles River Laboratories shares in Q2 2026, an estimated $18.9K.
  • Charles River Laboratories made up 0.03% of Cornerstone Investment Partners's portfolio in Q2 2026, its #58 holding.
  • Cornerstone Investment Partners first reported a position in Charles River Laboratories in Q4 2023 and has held it in 11 quarters since.
  • 260 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cornerstone Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.